ABSTRACT 2Ј-Pyridine ring substituted analogs of epibatidine were assessed for equilibrium binding affinity, functional potency, and efficacy at rat neuronal nicotinic receptors expressed in Xenopus oocytes. Binding affinities were determined in membrane homogenates from oocytes expressing ␣2␤2, ␣2␤4, ␣3␤2, ␣3␤4, ␣4␤2, or ␣4␤4. Efficacy (relative to acetylcholine) and potency were measured electrophysiologically with oocytes expressing ␣3␤4, ␣4␤2, and ␣4␤4. Hydroxy, dimethylamino, and trifluoromethanesulfonate analogs had affinities too low for accurate measurement. The bromo analog had affinities 4-to 55-fold greater at ␤2 than at ␤4-containing receptors, modestly greater efficacy at ␣4␤4 than at ␣4␤2, and 5-to 10-fold greater potency at a4␤4 than at ␣3␤4 or ␣4␤2. The fluoro analog displayed affinities 52-to 875-fold greater at ␤2-than at ␤4-containing receptors, efficacy at ␣4␤4 receptors 3-fold greater than at ␣4␤2 and ␣3␤4, and was equipotent at all receptors tested. The norchloro analog showed affinities 114-to 3500-fold greater at ␤2-than at ␤4-containing receptors, 2-fold greater efficacy at ␣4␤2 and ␣4␤4 than at ␣3␤4, and 4-to 5-fold greater potency at ␣4␤4 and ␣3␤4 than at ␣4␤2. The amino analog displayed affinities 10-to 115-fold greater at ␤2-than at ␤4-containing receptors, 3-fold greater efficacy at ␣3␤4 than at ␣4␤2, and 2-to 4-fold greater potency at ␣3␤4 and ␣4␤4 than at ␣4␤2. Although these compounds displayed a variety of differences in affinity, efficacy, and potency, with one exception (binding affinity and functional potency at ␣4␤4 receptors) there were no significant correlations among these properties.
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Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels assembled as pentamers of ␣ and ␤ subunits, forming a variety of different receptor subtypes. There are nine known ␣ subunits (␣2-␣10) and three known ␤ subunits (␤2-␤4) for neuronal nAChRs (Corringer et al., 2000; Elgoyhen et al., 2001 ). These subunits assemble in a variety of homomeric and heteromeric combinations to form receptors with different biophysical and pharmacological properties and with distinct distributions in the central and peripheral nervous systems (Corringer et al., 2000) . A predominant CNS nAChR is the ␣4␤2 subtype, whereas a predominant ganglionic nAChR is the ␣3␤4* subtype (Lucas et al., 1999; Xu et al., 1999; Picciotto et al., 2000; Quik et al., 2000) . Neuronal nAChR ligands with potential subtype selectivity are under investigation as analgesics (Qian et al., 1993; Rogers and Iwamoto, 1993; Badio and Daly, 1994) , anxiolytics (Decker et al., 1995; Brioni et al., 1997) , and as therapeutics for CNS disorders, including Alzheimer's Disease, Parkinson's Disease, and schizophrenia (Qian et al., 1993; Rogers and Iwamoto, 1993; Vidal, 1996; Brioni et al., 1997; Hellstrom-Lindahl et al., 1999) .
Epibatidine is a potent agonist at neuronal nAChRs (Badio and Daly, 1994; Gerzanich et al., 1995; Alkondon et al., 1998) . Epibatidine is reported to exhibit high-potency analgesic activity with a longer duration of action than nicotine (Qian et al., 1993; Rogers and Iwamoto, 1993; Badio and Daly, 1994) , and epibatidine analogs are currently under investigation as nonopioid analgesics. However, epibatidine is reported to produce various toxicities in rodents, including increased heart rate, motor incoordination, and seizure (Sullivan et al., 1994; Bonhaus et al., 1995; Horti et al., 1998) . The toxicity of epibatidine may arise from its capacity to activate many different neuronal nAChR subtypes. Separa-tion of the analgesic effects from the toxicities may be possible if subtype-selective analogs of epibatidine can be developed.
In this study, we examine the effects of modifying the epibatidine molecule on equilibrium binding affinity, efficacy, and functional potency at simple heteromeric neuronal nAChRs. In particular, we focus on the effect that 2Ј-pyridine ring substitutions have on selectivity for subunit combinations (␣4␤2 and ␣3␤4) representative of neuronal nAChRs found in the central and peripheral nervous systems, respectively.
Materials and Methods
Materials. Xenopus laevis frogs were purchased from Nasco (Ft. Atkinson, WI). Care and use of Xenopus frogs in this study have been approved by the University of Miami Animal Research Committee and meets the guidelines of the National Institutes of Health. RNA transcription kits were from Ambion (Austin, TX). [ 3 H]Epibatidine was from PerkinElmer Life Sciences (Boston, MA). Acetylcholine, (ϩ)-epibatidine, gentamicin, HEPES, polyethylenimine, and 3-aminobenzoic acid ethyl ester were from Sigma-Aldrich (St. Louis, MO). Collagenase B was from Roche Molecular Biochemicals (Indianapolis, IN). 934-AH glass microfiber filters were from Whatman (Clifton NJ).
Epibatidine Analogs. Norchloro-epibatidine (NEP), fluoro-norchloro-epibatidine (NFEP), bromo-norchloro-epibatidine (NBEP), amino-norchloro-epibatidine (NNEP), hydroxy-norchloro-epibatidine (NOHEP), dimethylamino-norchloro-epibatidine (NDMNEP), and trifluoromethanesulfonate-norchloro-epibatidine (NTEP) were synthesized as described previously (Carroll et al., 2001 ). All analogs are racemic. Structures are shown in Fig. 1 .
Expression of Neuronal nAChRs in Xenopus Oocytes. cDNA clones encoding rat ␣2, ␣3, ␣4, ␤2, and ␤4 subunits in the pGEMHE high-expression vector (Liman et al., 1992) were used for cRNA transcription. m 7 G(5Ј)ppp(5Ј)G-capped cRNA was synthesized in vitro from linearized template cDNA using an mMessage mMachine kit (Ambion). Mature X. laevis frogs were anesthetized by submersion in 0.1% 3-aminobenzoic acid ethyl ester and oocytes were surgically removed. Follicle cells were removed by treatment with collagenase B for 2 h at room temperature. Oocytes were injected with 8 to 18 ng of cRNA in 23 to 50 nl of water and incubated at 19°C in modified Barth's saline [88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO 3 , 0.3 mM Ca(NO 3 ) 2 , 0.41 mM CaCl 2 , 0.82 mM MgSO 4 , 100 g/ml gentamicin, 15 mM HEPES, pH 7.6] for 2 to 10 days. RNA transcripts encoding each subunit were injected into oocytes at a molar ratio of 1:1.
Competition Binding Assays. Crude membrane homogenates were prepared from Xenopus oocytes expressing various neuronal nAChR subunit combinations as described previously (Parker et al., 1998) . Briefly, up to 15 oocytes (depending on expression levels) were homogenized per milliliter of buffer containing 140 mM NaCl, 1.5 mM KCl, 2 mM CaCl 2 , 1 mM MgSO 4 , and 25 mM HEPES, pH 7.5, with 0.1 mM phenylmethylsulfonyl fluoride added immediately before the experiment, using a model PT 10/35 homogenizer (Brinkman, Atlanta, GA). Homogenates were centrifuged at 4°C at 2000g for 10 min. The supernatant was removed for use in experiments, avoiding both the surface lipid layer and the pellet. Receptor expression levels averaged 480 fmol/mg of total protein (16 fmol/oocyte).
Competition studies were performed using a reaction volume of 0.5 ml. The radioligand concentration in all reactions was 500 pM [ 3 H](Ϯ)-epibatidine, and the competing ligand concentration varied from 1 pM to 3 M. Reactions were initiated by the addition of oocyte homogenate (0.5-5 oocyte equivalents/tube) and were incubated at 25°C in a shaking water bath for 3.5 to 4.0 h. The reactions were stopped by filtration onto glass fiber filters (934-AH; Whatman) pretreated with 0.1% polyethylenimine using a model M-24 harvester (Brandel Inc., Gaithersburg, MD) and counted on an LS 6500 scintillation counter (Beckman Coulter, Inc., Fullerton, CA). Nonspecific binding was determined in parallel reactions containing 100 nM epibatidine. Nonspecific binding did not exceed 45%. We have observed similar levels of nonspecific binding using 1 mM nicotine and 100 M dimethylphenylpiperazinium (Parker et al., 1998 (Parker et al., , 2001 . Because of the variation in receptor expression level from day to day after injection of the oocytes and among oocyte batches, all results were normalized as the percentage of maximum specific binding.
In Table 1 (Cheng and Prusoff, 1973) . K d values shown in Table 1 were used in the calculation of K i .
Electrophysiological Methods. Agonist-induced current responses were measured under two-electrode voltage clamp, using a TEV-200A voltage-clamp unit (Dagan, Minneapolis, MN). Micropipettes were filled with 3 M KCl and were used at resistances of 0.3 to 2.0 M⍀. Current responses were recorded at a holding potential of Ϫ40 mV to minimize the contribution of calcium-activated chloride channels. Recordings were sampled at 100 Hz and filtered at 20 Hz (Ϫ3 db). Data was acquired, stored, and analyzed on a Macintosh G3 computer using AxoGraph 4.6 software (Axon Instruments, Union City, CA).
Oocytes were continuously perfused in perfusion solution (115 mM NaCl, 1.8 mM CaCl 2 , 2.5 mM KCl, 0.1 M atropine, and 10 mM HEPES, pH 7.2) at a rate of ϳ20 ml/min. Agonists were dissolved in perfusion solution and applied for 10 s, with 5-min washes between applications. Dose-response curves were determined for epibatidine and each analog as follows. Acetylcholine was applied before each test drug application at the EC 20 for acetylcholine for each receptor subunit combination (␣4␤2, 20 M; ␣3␤4, 110 M; and ␣4␤4, 5 M). Current responses to epibatidine and epibatidine analogs were normalized to the preceding acetylcholine-induced response, allowing determination of each test drug response relative to the maximum response to acetylcholine at each receptor. Initial experiments with epibatidine determined with and without this normalization resulted in different efficacies (Fig. 3A) . All subsequent experiments were normalized as described above.
Dose-response data were fit to the equation
, where I is the current response at agonist concentration (X), I max is the maximum current, EC 50 is the agonist concentration producing the half-maximal current response, and n H is the Hill coefficient. Data were fit by nonlinear regression using Prism 3.0a software (GraphPad Software, San Diego, CA). Statistical significance was determined by one-way analysis of variance with the Newman-Keuls post-test or by a two-tailed t test, as appropriate. r 2 values were determined by two-tailed Pearson correlation.
Results
Epibatidine Analogs. Seven racemic analogs of epibatidine, with substitutions at the 2Ј position of the pyridine ring, were synthesized as described previously (Carroll et al., 2001) . The structures of epibatidine and the analogs are shown in Fig. 1 Table 1 . Several analogs (NOHEP, NDMNEP, and NTEP) had affinities that were too low to accurately measure. Rough estimates of the affinities of these analogs for ␤2-containing receptors are provided in Table 1 . No estimates of affinity were obtained for ␤4-containing receptors. These three epibatidine analogs were not pursued further. All subsequent work in this study is focused on the four analogs with measurable affinities (NEP, NFEP, NBEP, and NNEP).
Similar to what we reported previously for epibatidine and other ligands (Parker et al., 1998) , the ␤2-containing receptors displayed higher affinities for the epibatidine analogs than did the ␤4-containing receptors. However, some of the analogs displayed much greater selectivity for ␤2-containing receptors over ␤4-containing receptors than we have observed with other compounds. Differences in affinity for different receptors based on the ␣ subunit were also observed, but the differences were modest. The binding affinities of epibatidine and the four analogs for the various neuronal nAChR subunit combinations are compared in Fig. 2 .
The bromo-substitution in NBEP resulted in an analog with affinities for the various subunit combinations that were very similar to those of epibatidine itself. The fluorosubstitution (NFEP) resulted in an analog with increased affinity for ␤2-containing receptors and decreased affinity for ␤4-containing receptors. The largest difference was seen for ␣3-containing receptors, with the ␣3␤2 receptor having a 550-fold higher affinity than the ␣3␤4 receptor. The norchloro analog (NEP) was also highly selective for ␤2-containing receptors. Again, the greatest difference in affinity was seen with ␣3␤2 and ␣3␤4 (a 3500-fold difference). The amino substitution (NNEP) caused a loss of affinity for both ␤2-and ␤4-containing receptors; however, NNEP remained selective for ␤2 receptors over ␤4 receptors.
Electrophysiological Analysis. We examined the functional potency and efficacy of (ϩ)-epibatidine and the four analogs that displayed measurable equilibrium binding affinities (NBEP, NFEP, NEP, and NNEP) for activation of three neuronal nAChR subunit combinations. ␣4␤2 is a major subtype in the CNS, whereas ␣3␤4 represents a subtype (␣3␤4*) found in the periphery (for explanation of nomenclature, see Lucas et al., 1999) . The ␣4␤4 subunit combination was also examined as a point of comparison between ␣4␤2 and ␣3␤4.
To investigate the wide variation in the efficacy of epibatidine at the ␣4␤2 receptor reported in the literature (see Discussion), we initially constructed concentration-response curves for epibatidine at ␣4␤2 receptors using two different protocols (Fig. 3A) . In both protocols, three applications of acetylcholine (20 M, the EC 20 for ␣4␤2 receptors) were given before epibatidine applications to ensure stability of responses. In the first protocol, the epibatidine dose-response curve was determined by measuring epibatidine responses in succession and normalizing to the ACh response immediately preceding the first epibatidine response. In the second protocol, a normalizing ACh application (20 M) was added before each epibatidine application to correct for possible receptor desensitization or inactivation after repeated agonist application. When dose-response curves for epibatidine were determined by the first method, an efficacy of 25 Ϯ 3% (relative to the maximum ACh response) was obtained. When dose-response curves were determined by the second method, an efficacy of 58 Ϯ 6% was obtained. Although the efficacy values determined by the two methods were quite different Our observation that the measured efficacy of epibatidine varies depending on the normalization method (Fig. 3A) suggested that epibatidine may be causing a long-lasting inactivation of the receptors. To test this idea, we examined the effect of high concentrations of ACh or epibatidine on subsequent responses to ACh (Fig. 3B) . Agonists were applied to ␣4␤2-expressing oocytes for 10 s at 5-min intervals. Three applications of 20 M ACh were followed by an application of 75 M ACh, or a concentration of epibatidine (45 nM), yielding a similar degree of receptor activation. Three more applications of 20 M ACh followed. These last three applications of 20 M ACh are plotted in Fig. 3B as a percentage of the 20 M ACh application immediately preceding application of the high concentration of ACh or epibatidine. Although application of the high concentration of ACh had no effect on subsequent ACh responses, application of the high concentration of epibatidine resulted in a decrease in subsequent ACh responses. This effect of epibatidine did not reverse after 15 min of washing. In light of this apparent inactivation of a portion of the receptors upon epibatidine exposure, we decided to use the second method (renormalizing after each epibatidine application) in all subsequent work.
In addition to ␣4␤2, we also examined epibatidine activation of the ␣3␤4 and ␣4␤4 receptors. Figure 3C compares the epibatidine dose-response curves for ␣4␤2, ␣3␤4, and ␣4␤4 receptor subtypes. At ␣4␤4 receptors, epibatidine exhibited an efficacy of 71 Ϯ 7%, similar to the efficacy at ␣4␤2 receptors. At the ␣3␤4 receptor, epibatidine exhibited an efficacy of 39 Ϯ 3%, significantly lower than at either the ␣4␤2 or ␣4␤4 receptor.
The fluoro-substituted analog (NFEP) displayed the greatest improvement in subtype selectivity (in terms of efficacy). Dose-response curves for NFEP at each receptor subtype are shown in Fig. 3D . Although NFEP exhibited high efficacy at ␣4␤4 receptors (131 Ϯ 9%), efficacies were significantly lower at ␣4␤2 and ␣3␤4 receptors (41 Ϯ 10 and 40 Ϯ 3%, respectively). Although NFEP produced differences in maximum response, the EC 50 values were similar for the three receptor subtypes (Table 2) . Dose-response curves were also constructed for NBEP, NEP, and NNEP activation of ␣4␤2, ␣3␤4, and ␣4␤4 receptors. Efficacies relative to ACh for epibatidine and the four analogs are compared in Fig. 4 . Efficacy, EC 50 , and n H values are provided in Table 2. NBEP exhibited efficacies similar to ACh at ␣4␤2, ␣3␤4, and ␣4␤4 receptors (65 Ϯ 8, 82 Ϯ 20, and 102 Ϯ 10%, respectively). The efficacy at ␣4␤2 receptors was significantly less than at ␣4␤4 receptors. NBEP was significantly less potent at ␣4␤2 (EC 50 ϭ 94 Ϯ 6 nM) and ␣3␤4 (EC 50 ϭ 189 Ϯ 51 nM) receptors relative to ␣4␤4 (EC 50 ϭ 20 Ϯ 8 nM).
The amino-substituted analog (NNEP) was the only analog to display selectivity (in terms of efficacy) for the ␣3␤4 receptor over the ␣4␤2 receptor. NNEP displayed an efficacy at the ␣3␤4 receptor (82 Ϯ 20%) that was similar to ACh, whereas the efficacy of NNEP at the ␣4␤2 receptor was significantly lower (29 Ϯ 4%). NNEP was less potent at ␣4␤2 (EC 50 ϭ 7600 Ϯ 627 nM) than at ␣3␤4 (EC 50 ϭ 3240 Ϯ 449 nM) and at ␣4␤4 (EC 50 ϭ 1840 Ϯ 622 nM).
NEP exhibited high efficacy at both ␣4␤2 and ␣4␤4 receptors (112 Ϯ 19 and 147 Ϯ 34%, respectively). This analog exhibited a significantly lower efficacy of 61 Ϯ 10% at ␣3␤4 receptors. NEP was less potent at ␣4␤2 receptors (EC 50 ϭ 3630 Ϯ 646 nM) than at ␣3␤4 (EC 50 ϭ 702 Ϯ 57 nM) and ␣4␤4 (EC 50 ϭ 982 Ϯ 54 nM).
Discussion
In this study, we have examined the equilibrium binding affinities and functional activities of several epibatidine an- (Parker et al., 1998) are shown for reference. All values are mean Ϯ S.E.M. of two to three experiments, each performed in sextuplicate.
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at ASPET Journals on August 30, 2017 jpet.aspetjournals.org alogs at neuronal nAChRs expressed in Xenopus oocytes. We found that the epibatidine analogs with measurable binding affinities were selective for ␤2-containing receptors over ␤4-containing receptors. This is similar to what we have previously reported using epibatidine and several common agonists (Parker et al., 1998) . However, the degree of selectivity was much greater than in our previous work. In particular, the fluoro-substituted (NFEB) and norchloro (NEP) analogs of epibatidine showed several hundred-to several thousandfold selectivity for ␤2-containing receptors. In general, substitution of the 2Ј chlorine of epibatidine with electron-withdrawing groups, such as the fluoro and bromo groups, or the neutral hydrogen, resulted in analogs with high affinity for ␤2-containing receptors and low, but measurable affinities for ␤4-containing receptors. Substitution with electron-donating groups (hydroxy and dimethylamino) resulted in affinities for all subunit combinations that were too low to accurately measure. However, effects on affinity could not be attributed solely to electron-donating or -withdrawing properties of the substituents. Substitution with the electron- withdrawing trifluoromethanesulfonate group produced an analog with a very low affinity for all subunit combinations, perhaps due to the large increase in steric bulk. Also, substitution with the electron donating amino group resulted in an analog with moderate affinities for some subunit combinations.
Although the great increase in selectivity seen in the equilibrium binding assays was promising, the affinity values for the analogs derived from the binding assay were not generally predictive of the relative potencies determined in the functional assay (Tables 1 and 2 ). For example, the equilibrium binding of NFEP for the ␣4␤2 receptor was 228-fold greater than the affinity for the ␣3␤4 receptor. However, NFEP displayed equal functional potency at the ␣4␤2 and ␣3␤4 receptors. NEP provides an even more striking example. Although the binding affinity of NEP was 1300-fold greater for ␣4␤2 than for ␣3␤4, the functional potency of NEP was 5-fold greater at the ␣3␤4 receptor than at the ␣4␤2 receptor. For both ␣4␤2 and ␣3␤4, the functional potency of epibatidine and the four analogs failed to correlate with the equilibrium binding affinity (Table 3) . However, for ␣4␤4 there was a significant correlation between functional potency and equilibrium binding affinity.
The affinity measured in our binding assay reflects a distribution of receptor states. Because the receptors are in equilibrium between closed, open, and desensitized states, the binding affinity measured is dependent on agonist affinities for the individual states as well as the equilibrium constants for transitions among the different states. The desensitized state of the receptor has an exceptionally high affinity for agonists. Furthermore, the open activated state of the receptor is transient, and in our binding assay, the agonist concentration is too low for significant binding to the closed state of the receptor. This suggests that the equilibrium binding affinity predominantly reflects the affinity of agonists for the desensitized state. Because of the higher affinity of agonists for this state, equilibrium binding affinities are 2 to 4 orders of magnitude higher than that for the closed activateable state (estimated from EC 50 values for activation) measured in functional assays (Harvey and Luetje, 1996; Parker et al., 1998) . The affinity of epibatidine for the closed activateable state and the desensitized state has been reported to differ by ϳ3 orders of magnitude, depending on receptor subunit combination (Gerzanich et al., 1995; Gopalakrishnan et al., 1996) . Thus, independent variation in ligand affinity for different states of the receptors may underlie the differences in selectivity measured in equilibrium binding assays and functional potency assays of the epibatidine analogs studied herein. The large effect of 2Ј-pyridine ring substitutions on ␤ subunit selectivity in equilibrium binding assays that we have observed is interesting in light of the recently reported computational docking of epibatidine into the binding site of a homology model of the extracellular domain of an ␣7 homomeric neuronal nAChR (Le Novere et al., 2002) . In this model, which is suggested to represent the desensitized form of the receptor, the 2Ј-pyridine chlorine of epibatidine interacts with residues of the "complementary component" of the binding pocket. In heteromeric neuronal nAChRs, such as ␣4␤2 and ␣3␤4, the complementary component is supplied by the ␤ subunit. Although the selectivity in equilibrium binding assays will be of use in experimental identification of receptor subunit composition, identification of analogs of potential therapeutic usefulness requires assessment of functional potency and efficacy.
The reported efficacy of epibatidine for activation of ␣4␤2 receptors varies from ϳ20 to ϳ100% of the maximum ACh response (Gerzanich et al., 1995; Buisson et al., 2000; Spang et al., 2000) . We have found that the measured efficacy of epibatidine is dependent on the method used to normalize the data (Fig. 3A) . If the responses to epibatidine are recorded in succession and normalized to an ACh response that precedes the entire series of epibatidine responses, the measured efficacy is quite low (25 Ϯ 3%). If normalizing ACh responses are interleaved between the epibatidine responses then the measured efficacy is higher (58 Ϯ 6%). This difference seems to be due to exposure to epibatidine causing an inactivation of a portion of the receptors. This inactivated state seems to be relatively long-lived, because the receptors do not reappear even after extensive washing (Fig. 3B) . Buisson et al. (2000) also observed this effect of epibatidine, proposing that epibatidine remains tightly bound, maintaining the receptor in a nonactivatable state. The remaining functional receptors did not seem to be affected, because EC 50 values, Hill coefficients, and desensitization rates before and after epibatidine exposure were the same (Buisson et al., 2000) . This effect of epibatidine supports the necessity of repeated ACh normalization during epibatidine and analog efficacy measurements. We also observed decreases in the amplitude of the normalizing ACh applications after application of the various epibatidine analogs (data not shown).
Similar to what we observed for functional potencies, equilibrium binding affinity values for the epibatidine analogs were not generally predictive of the relative efficacies determined in the functional assay (Tables 1 and 2 ). For example, although NEP was selective for ␣4␤2 over ␣3␤4 in the binding assay (1300-fold) and the efficacy assay (2-fold), NFEP was selective for ␣4␤2 over ␣3␤4 (228-fold) and ␣4␤4 (52-fold) in the binding assay, but was selective for ␣4␤4 over ␣4␤2 and ␣3␤4 (3-fold) in the efficacy assay. Another striking example is provided by NNEP, which had a 20-fold greater affinity for ␣4␤2 receptors than for ␣3␤4 receptors, but was 3-fold more efficacious at ␣3␤4 receptors than at ␣4␤2 receptors. There were no significant correlations between equilibrium binding affinity and efficacy for ␣4␤2, ␣3␤4, or ␣4␤4 (Table 3) .
The large increases in neuronal nAChR subtype selectivity that we observed in equilibrium binding assays with several epibatidine analogs suggested that these analogs might have useful functional selectivity for CNS neuronal nAChRs (typified by ␣4␤2) over peripheral neuronal nAChRs (typified by ␣3␤4). However, differences in functional potency and efficacy were modest, suggesting that these analogs are unlikely to be selective enough for CNS neuronal nAChRs over peripheral nAChRs to avoid peripheral toxicity. This has been jpet.aspetjournals.org a problem with other epibatidine analogs. Halogen-substituted and methylated analogs of epibatidine have been reported to produce fewer toxicities in rodents (Badio et al., 1997; Horti et al., 1998) ; however, the reduction in toxic effects seen in these studies was not sufficient to ensure safe therapeutic/toxicity ratios. Epiboxidine, a methylisoxazole analog of epibatidine has also been reported to produce fewer toxicities than epibatidine in mice (Badio et al., 1997) . However, epiboxidine was less potent than epibatidine as an antinociceptive agent and, in sodium flux assays, was not significantly less potent than epibatidine at ganglionic nAChRs. Thus, the development of CNS-selective epibatidine analogs will require continued effort. The general failure of efficacy and functional potency to correlate with binding affinity (Table 3) indicates that a combined physiological and pharmacological approach for determination of binding affinity, efficacy, and functional potency will be required for the development of epibatidine analogs with improved functional subtype selectivity.
